Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-09 |
2024-03 |
-0.44 |
-0.36 |
0.08 |
18.18% |
2024-03-19 |
2023-12 |
-0.38 |
-0.34 |
0.04 |
10.53% |
2023-11-08 |
2023-09 |
-0.55 |
-0.48 |
0.07 |
12.73% |
2023-08-10 |
2023-06 |
-0.58 |
-0.54 |
0.04 |
6.90% |
2023-05-10 |
2023-03 |
-0.66 |
-0.55 |
0.11 |
16.67% |
2023-03-22 |
2022-12 |
-0.72 |
-0.63 |
0.09 |
12.50% |
Date |
Firm |
Action |
From |
To |
2023-10-10 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-10 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-06-04 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-29 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-10 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-04-27 |
Ladenburg Thalmann |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2018-12-06 |
ALDRICH RICHARD H |
Director |
136.85K |
Stock Award(Grant) |
2022-01-06 |
DUBENSKY THOMAS W |
President |
113.34K |
Purchase |
2018-12-06 |
FISHER MARY |
Director |
3.32K |
Stock Award(Grant) |
2018-12-06 |
GALLAGHER CAROL GILTNER |
Director |
0.00 |
Stock Award(Grant) |
2018-12-06 |
KOZIN MARC D |
Director |
7.74K |
Stock Award(Grant) |
2021-06-24 |
LORENZO PIERRE |
Officer |
53.00 |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
EcoR1 Capital, LLC |
1.12M |
1.43M |
8.43% |
2023-06-29 |
FMR, LLC |
647.90K |
822.83K |
4.86% |
2023-06-29 |
Rock Springs Capital Management, LP |
536.21K |
680.99K |
4.02% |
2023-06-29 |
AIGH Capital Management LLC |
406.25K |
515.94K |
3.05% |
2023-06-29 |
Vanguard Group Inc |
309.84K |
393.50K |
2.33% |
2023-06-29 |
Sectoral Asset Management, Inc. |
219.39K |
278.63K |
1.65% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Extended Market Index Fund |
154.15K |
195.77K |
1.16% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
147.14K |
186.87K |
1.10% |
2023-05-30 |
Fidelity Extended Market Index Fund |
47.48K |
72.65K |
0.36% |
2023-05-30 |
Fidelity Total Market Index Fund |
24.14K |
36.93K |
0.18% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
18.69K |
28.60K |
0.14% |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
11.41K |
17.46K |
0.09% |
Split |
Date |
1 : 15 |
2021-06-28 |
1 : 15 |
2021-06-25 |
1 : 15 |
2018-12-10 |